Financial Performance - The company incurred significant net losses of $24.2 million for the year ended December 31, 2025, and $131.2 million for the year ended December 31, 2024[188]. - As of December 31, 2025, the company had total stockholders' equity of $53.5 million and cash, cash equivalents, and short-term investments of $77.8 million[188][191]. - The company has never generated revenue from product sales and does not anticipate doing so for the next several years[189]. Funding and Capital Needs - The company closed private investments generating $92.1 million in October 2023 and $105.0 million in February 2025[191]. - The company plans to finance its cash needs through public or private equity offerings, debt financings, and collaborations[195]. - The company expects to fund operations into the third quarter of 2026, indicating a need for additional capital[195]. Going Concern and Audit Concerns - The independent auditor's report for the year ended December 31, 2025, raised substantial doubt about the company's ability to continue as a going concern[201]. - The company has incurred significant operating losses since its inception and expects to continue incurring substantial capital for research and development[197]. Drug Development and Clinical Trials - The company is in early or mid-stages of drug development, with ongoing clinical trials for advanced drug candidates in multiple countries, including the United States, Canada, and throughout Asia and Europe[213]. - The company has not yet demonstrated the ability to successfully complete registrational clinical trials or obtain marketing approvals[188]. - The company has halted development of drug candidates ALG-010133 and ALG-020572 due to insufficient antiviral activity and serious adverse events, respectively[213]. - Significant delays in clinical trials may occur due to public health pandemics, affecting patient enrollment and site initiation[208]. - The company acknowledges that any delays in clinical trials could harm the commercial prospects of its drug candidates and delay revenue generation[236]. Regulatory and Market Challenges - The regulatory approval process is lengthy and complex, with no guarantee that any drug candidates will receive approval[226]. - The company must comply with varying regulatory requirements in different countries, which may require significant resources[218]. - The company has not previously submitted a new drug application (NDA) to the FDA, which may complicate future regulatory approvals[216]. - The success of drug candidates depends on various factors, including financial resources, successful clinical trials, and regulatory approvals, which are inherently unpredictable[219]. Competition and Market Dynamics - The life sciences industry is highly competitive, with major pharmaceutical companies having greater resources and capabilities, which could negatively impact the company's commercial opportunities[298]. - The company faces competition from various pharmaceutical companies developing next-generation treatments for obesity and MASH, including established players like Novo Nordisk and Eli Lilly[300][301]. - Competitors may develop more effective or timely therapies, impacting funding and demand for the company's potential therapies[252]. Healthcare Reform and Pricing Pressures - Current and future healthcare reform legislation may increase commercialization difficulties and affect pricing, potentially harming the company's business[329]. - The Inflation Reduction Act (IRA) requires manufacturers to negotiate drug prices with Medicare, which could significantly impact the pharmaceutical industry[335]. - Future healthcare reform measures could limit prices for drug candidates and reduce government payments for healthcare products, leading to pricing pressure and reduced demand[341]. Manufacturing and Supply Chain Risks - The company does not own manufacturing facilities and relies on third-party manufacturers, increasing the risk of supply disruptions[371]. - The reliance on third-party CROs and manufacturers may lead to unexpected cost increases and delays in drug candidate commercialization[369]. - Changes in manufacturing processes may require FDA review, potentially delaying product development[376]. Legal and Compliance Risks - The company may face substantial liabilities from product liability lawsuits, which could limit the commercialization of approved products[327]. - Compliance with evolving data privacy and protection laws could result in government investigations, penalties, and adverse publicity, negatively impacting financial condition[342]. - Cybersecurity risks are increasing due to sophisticated attacks, which could disrupt operations and lead to material losses if sensitive data is compromised[354]. Collaboration and Partnership Challenges - Reliance on third-party collaborations for drug development poses risks; unsuccessful collaborations may hinder market potential for drug candidates[355]. - The company may need to establish additional collaborations to fund drug candidate development, which could incur non-recurring charges and increase expenditures[358]. - Significant competition exists in securing strategic partnerships, and the negotiation process is complex and time-consuming[359].

Financial Performance - Aligos reported a net loss of $19.9 million for Q4 2025, a significant reduction from a net loss of $82.2 million in Q4 2024, resulting in a basic and diluted net loss per share of $(1.91) compared to $(13.08) in the prior year[9][22]. - For the full year 2025, the net loss was $24.2 million, down from $131.2 million in 2024, with a basic and diluted net loss per share of $(2.45) versus $(20.94) in 2024[10][22]. Cash and Investments - Cash, cash equivalents, and investments totaled $77.8 million as of December 31, 2025, an increase from $56.9 million at the end of 2024, expected to fund operations into Q3 2026[8][25]. Research and Development Expenses - Research and development (R&D) expenses for Q4 2025 were $17.0 million, slightly up from $16.0 million in Q4 2024, primarily due to increased costs for the pevifoscorvir sodium Phase 2 clinical trial[11][22]. - Total R&D expenses for the year 2025 were $69.5 million, a decrease from $70.3 million in 2024, attributed to increased government funding for the coronavirus program[12][22]. General and Administrative Expenses - General and administrative (G&A) expenses for Q4 2025 were $4.9 million, down from $5.2 million in Q4 2024, mainly due to reduced legal and related expenses[13][22]. Clinical Trials and Studies - The Phase 2 B-SUPREME study of pevifoscorvir sodium completed enrollment of 60 HBeAg- participants in January 2026, with interim analyses expected in 2026[5][2]. - Aligos is advancing ALG-170675 into IND-enabling studies in partnership with Xiamen Amoytop Biotech, with development costs in China funded by Amoytop[2][5]. Product Development and Commercialization - The combination therapy of ALG-055009 with incretin receptor agonists showed a maximum body weight loss of 39% compared to monotherapy, indicating potential for significant weight loss benefits[17][4]. - The company appointed James Hassard as Executive Vice President, Chief Commercial Officer, to enhance its global commercial capabilities[7][22].

Core Insights - Aligos Therapeutics, Inc. reported significant progress in its clinical studies and financial results for Q4 and full year 2025, focusing on therapies for liver and viral diseases [1][2]. Recent Business Progress - The company is advancing its global Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection, with enrollment in both HBeAg- and HBeAg+ cohorts ongoing [2][5]. - Aligos has partnered with Xiamen Amoytop Biotech Co., Ltd. to advance ALG-170675, a dual mechanism antisense oligonucleotide (ASO), into IND-enabling studies [2][5]. - The appointment of James Hassard as Executive Vice President, Chief Commercial Officer, aims to enhance the company's global commercial capabilities [7]. Pipeline Updates - Pevifoscorvir sodium is positioned as a potential first-/best-in-class small molecule for chronic HBV infection [3]. - ALG-170675 is being developed as a potential best-in-class ASO for chronic HBV infection [4]. - ALG-055009 shows promise as a small molecule for obesity and metabolic dysfunction-associated steatohepatitis (MASH), with recent studies indicating significant weight loss benefits when combined with other therapies [4][6]. Financial Results - As of December 31, 2025, the company reported cash, cash equivalents, and investments totaling $77.8 million, an increase from $56.9 million in 2024, expected to fund operations into Q3 2026 [8]. - The net loss for Q4 2025 was $19.9 million, a significant reduction from a net loss of $82.2 million in Q4 2024 [9]. - For the full year 2025, the net loss was $24.2 million, down from $131.2 million in 2024 [10]. - Research and development expenses for Q4 2025 were $17.0 million, slightly up from $16.0 million in Q4 2024, primarily due to increased costs associated with the pevifoscorvir sodium Phase 2 trial [11]. - General and administrative expenses for Q4 2025 were $4.9 million, down from $5.2 million in Q4 2024, attributed to reduced legal and related expenses [13].

Core Viewpoint - Aligos Therapeutics, Inc. is set to report its fourth quarter 2025 financial results on March 5, 2026, before the U.S. financial markets open [1] Company Overview - Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company focused on developing best-in-class therapies for liver and viral diseases [2] - The company aims to improve patient outcomes through a science-driven approach and deep R&D expertise, targeting high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses [2]

Core Insights - Aligos Therapeutics, Inc. announced positive data from two presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) held from February 22 to 25, 2026, in Denver, Colorado [1][3] Group 1: Pevifoscorvir Sodium - The presentation on pevifoscorvir sodium highlighted a Phase 1 monotherapy study for chronic hepatitis B virus (HBV) infection, showcasing high viral suppression in subjects [2][4] - Pevifoscorvir sodium is being investigated as a potential first-/best-in-class small molecule CAM-E for chronic HBV infection [4] Group 2: ALG-097558 - The ALG-097558 presentation focused on pharmacokinetics in participants with hepatic and renal impairment, indicating its potential as a best-in-class ritonavir-free small molecule pan-coronavirus protease inhibitor [2][4] - ALG-097558 has received funding from federal agencies, including the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH) [2] Group 3: Company Overview - Aligos Therapeutics is a clinical-stage biotechnology company dedicated to developing best-in-class therapies for liver and viral diseases, with a focus on high unmet medical needs such as chronic HBV infection and coronaviruses [5]

Core Insights - Aligos Therapeutics is progressing with the Phase 2 B-SUPREME study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection, with interim analyses scheduled for 2026 [1][2] Study Progress - The Phase 2 B-SUPREME study currently has 144 subjects enrolled globally, with expectations for interim analyses to provide insights on study tracking [2] - The first interim analysis will include approximately 60% (36) of HBeAg- participants who have completed 12 weeks of treatment, expected in the first half of 2026 [3] - A second interim analysis is planned for when about 50% (55) of HBeAg+ participants complete 24 weeks of treatment, anticipated in the second half of 2026 [4] Regulatory Compliance - To maintain study integrity and comply with FDA regulations, the company will remain blinded to subject-level data and will receive insights from the Data Safety Monitoring Board [5] Leadership Update - Hardean Achneck, MD has resigned as Executive Vice President and Chief Medical Officer, and a search for his successor is underway [6] Study Details - The Phase 2 B-SUPREME study is a randomized, double-blind, active-controlled multicenter trial evaluating the safety and efficacy of ALG-000184 monotherapy compared to tenofovir disoproxil fumarate in approximately 200 untreated adult subjects with chronic HBV infection for 48 weeks [7] - The primary endpoint for HBeAg- participants is HBV DNA <LLOQ (10 IU/mL), while for HBeAg+ participants, it is also HBV DNA <LLOQ (10 IU/mL) [7] Product Information - Pevifoscorvir sodium, previously known as ALG-000184, is a potential first-in-class oral small molecule capsid assembly modulator being developed for chronic HBV infection [8] - Phase 1 studies have shown that pevifoscorvir sodium is well-tolerated, with no safety signals and demonstrated linear pharmacokinetics and excellent antiviral activity [8]

Core Insights - Aligos Therapeutics has appointed James Hassard as Executive Vice President and Chief Commercial Officer to enhance its global commercial capabilities [1][2] - The company is advancing the Phase 2 B-SUPREME study of pevifoscorvir sodium and is preparing for its commercial launch [2] - Aligos focuses on developing therapies for liver and viral diseases, with a strong emphasis on chronic hepatitis B virus infection and other high unmet medical needs [3] Company Overview - Aligos Therapeutics, Inc. is a clinical stage biotechnology company dedicated to improving patient outcomes through innovative therapies for liver and viral diseases [3] - The company utilizes a science-driven approach and has a purpose-built pipeline targeting conditions such as chronic hepatitis B virus infection, obesity, metabolic dysfunction-associated steatohepatitis, and coronaviruses [3] Leadership Background - James Hassard brings extensive experience in building commercial organizations across various therapeutic areas, having previously served as Chief Commercial Officer at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals [2] - His career includes significant roles at Coherus Oncology, Amgen, and Merck, where he launched multiple pharmaceutical products in areas including hepatitis, oncology, and nephrology [2] - Hassard holds a Bachelor of Science in Pharmacology and an MBA, indicating a strong educational background relevant to his new role [2]

Core Insights - Aligos Therapeutics, Inc. announced positive data from four presentations at the HEP-DART 2025 Meeting, showcasing advancements in therapies for liver and viral diseases [1][2] Pevifoscorvir Sodium Data - The Phase 1 monotherapy study of pevifoscorvir sodium for chronic hepatitis B virus (HBV) infection demonstrated its potential as a first-line therapy, with complete 96-week and post-treatment follow-up data indicating continued efficacy [3][6] ALG-055009 Data - New in vivo data from studies on diet-induced obese mice showed that the combination of ALG-055009 with incretin receptor agonists resulted in significant weight loss, with SEMA monotherapy achieving a maximum of 23.9% body weight loss, while the combination with ALG-055009 led to an additional 8.6% decrease for a total of 33% [4][5] - TIRZEP monotherapy resulted in a maximum of 27.1% and 34.4% body weight loss for low and high doses respectively, with combinations yielding up to 40% weight loss [4][5] Synergistic Effects - The combination therapy of ALG-055009 with incretin receptor agonists primarily resulted in fat mass loss without significantly affecting lean mass or food consumption, indicating a beneficial addition to existing therapies for weight loss [5][6] Future Directions - The company expressed enthusiasm for the potential of both pevifoscorvir sodium and ALG-055009, highlighting their commitment to advancing next-generation therapies for chronic HBV and metabolic diseases [6][9]

Core Insights - Aligos Therapeutics has a significant Phase II pipeline, with a focus on hepatitis B treatment through its lead program, pevifoscorvir (previously known as ALG-184) [2][3] - The company is also developing a beta thyroid agonist, ALG-009, which has completed Phase IIa testing, along with preclinical results in obesity [2] - Additionally, Aligos is working on a pan-coronavirus protease inhibitor currently in a Phase II study funded by the MRC in the U.K. [3] Company Pipeline - The lead program, pevifoscorvir, targets chronic hepatitis B virus (HBV) infection, which is recognized as the largest chronic viral infection globally [2][3] - The beta thyroid agonist, ALG-009, has shown promising results in Phase IIa testing [2] - The preclinical portfolio includes an antisense oligonucleotide targeting both hepatitis B and hepatitis delta viruses [3]

Summary of Aligos Therapeutics Conference Call Company Overview - **Company**: Aligos Therapeutics (NasdaqCM:ALGS) - **Event**: Jefferies' London Healthcare Conference - **Date**: November 17, 2025 Key Points on Aligos Therapeutics and its Pipeline Lead Programs - **PEVY/PhosCovir**: Lead program targeting hepatitis B, previously known as ALG-000184 [2][3] - **ALG-009**: A beta thyroid agonist that has completed phase 2A testing, with potential applications in obesity and metabolic diseases [2][20] - **Pan-coronavirus protease inhibitor**: Currently undergoing a phase 2 study in the UK funded by the MRC [2] Hepatitis B Virus (HBV) Insights - **Prevalence**: Approximately 250 million patients globally, with significant populations in China (70 million), the US (2-2.5 million), and Western Europe (14 million) [3] - **Current Treatments**: Standard care includes nucleoside analogs and pegylated interferon, but these have limitations, including progression to end-stage liver disease and liver cancer [4][5] - **Unmet Medical Need**: A study indicated that 4% of patients on nucleoside therapy developed hepatocellular carcinoma over five years, highlighting the need for more effective treatments [4] Mechanism of Action for PEVY - **Capsid Assembly Modulators**: PEVY is designed to block both the replication of HBV and the establishment of cccDNA, which is crucial for the virus's persistence [8][9] - **Pharmacological Improvements**: Oral bioavailability of PEVY was increased from 5% to 80% through laboratory modifications [9] - **Clinical Results**: In early studies, PEVY demonstrated significant reductions in HBV DNA, outperforming standard nucleoside therapies [11][12] Clinical Trial Data - **Efficacy**: By week 48, 60% of E positive patients were below the limit of quantitation for HBV DNA, and 100% of E negative patients achieved similar results [12][13] - **Comparison with Standard Care**: PEVY showed a greater log reduction in HBV DNA compared to tenofovir, a standard nucleoside analog [11][13] - **Safety Profile**: No patients discontinued therapy due to adverse events, indicating a favorable safety profile [15] Future Directions - **Ongoing Studies**: A phase 2 clinical study comparing PEVY to TDF is underway, with an interim analysis expected early next year [17][19] - **Potential for Standard of Care**: PEVY is positioned to become the standard for chronic suppression of HBV, especially for patients not eligible for functional cure therapies [19] ALG-009 Developments - **Potency and Selectivity**: ALG-009 has shown to be significantly more potent than existing beta thyroid agonists, with a favorable pharmacokinetic profile [20][21] - **Phase 2b Readiness**: The drug is ready to enter phase 2b trials, with promising data on fat reduction in liver disease [21] Additional Insights - **Resistance Mechanism**: PEVY has shown no emergence of drug-resistant variants in clinical studies, which is a significant advantage over previous capsid assembly modulators [24][25] - **Regulatory Considerations**: The ability to conduct monotherapy with PEVY is crucial for FDA approval for chronic suppression, differentiating it from previous therapies that required combination treatments [25] This summary encapsulates the critical aspects of Aligos Therapeutics' conference call, focusing on their innovative approaches to treating hepatitis B and metabolic diseases, as well as the promising data from their clinical trials.